EML4-ALK fusion gene in non-small cell lung cancer

Oncol Lett. 2022 Jun 24;24(2):277. doi: 10.3892/ol.2022.13397. eCollection 2022 Aug.

Abstract

Non-small cell lung cancer (NSCLC) is a malignant tumor with a high morbidity and mortality rate that is a threat to human health. With the development of molecular targeted research, breakthroughs have been made on the molecular mechanism of lung cancer. The echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene is one of the most important pathogenic driver genes of NSCLC discovered thus far. Four generations of targeted drugs for EML4-ALK have been developed, with patients benefiting significantly from these drugs. Therefore, EML4-ALK has become a research hotspot in NSCLC. The aim of the present study is to introduce the current research progress of EML4-ALK and its association with NSCLC.

Keywords: EML4-ALK; fusion gene; non-small cell lung cancer; targeted therapy.

Publication types

  • Review

Grants and funding

Funding: Not applicable.